for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jiangsu Hengrui Medicine Co Ltd

600276.SS

Latest Trade

93.73CNY

Change

1.88(+2.05%)

Volume

29,210,344

Today's Range

91.53

 - 

95.00

52 Week Range

57.18

 - 

96.47

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
91.85
Open
91.80
Volume
29,210,344
3M AVG Volume
501.95
Today's High
95.00
Today's Low
91.53
52 Week High
96.47
52 Week Low
57.18
Shares Out (MIL)
4,422.81
Market Cap (MIL)
414,550.40
Forward P/E
--
Dividend (Yield %)
--

Next Event

Jiangsu Hengrui Medicine Co Ltd Annual Shareholders Meeting

Latest Developments

More

Jiangsu Hengrui Medicine's 2019 Net Profit Up 31.1% Y/Y

Jiangsu Hengrui Medicine's Board Elects Chairman

Jiangsu Hengrui Medicine's 9-Mth Net Profit Up 28.3% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jiangsu Hengrui Medicine Co Ltd

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.

Contact Info

No.7 Kunlunshan Road

Lianyungang Eco & Tech Development Zone

LIANYUNGANG, JNG

222000

China

+86.518.81220012

http://www.hrs.com.cn

Executive Leadership

Yunshu Zhou

Chairman of the Board, General Manager

Song Zhou

Chief Financial Officer

Hongbin Dai

Deputy General Manager, Director

Jieping Sun

Deputy General Manager, Director

Lianshan Zhang

Deputy General Manager, Director

Key Stats

1.78 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

13.8K

2018

17.4K

2019

23.3K

2020(E)

29.7K
EPS (CNY)

2017

0.728

2018

0.917

2019

1.205

2020(E)

1.512
Price To Earnings (TTM)
77.72
Price To Sales (TTM)
17.80
Price To Book (MRQ)
16.66
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.27
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
23.82
Return on Equity (TTM)
21.34

Latest News

Latest News

BRIEF-Jiangsu Hengrui Medicine's 2019 Net Profit Up 31.1% Y/Y

* SAYS 2019 NET PROFIT UP 31.1% Y/Y AT 5.3 BILLION YUAN ($747.00 million) Source text in Chinese: https://bit.ly/3ae0tHY Further company coverage: ($1 = 7.0950 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Jiangsu Hengrui Medicine unit passes U.S. FDA approval

* Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Health and Youth Care Inspectorate

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine gets approval for clinical trials of drugs

* Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y

* Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million)

BRIEF-Jiangsu Hengrui Medicine passes FDA approval

* Says it received approval for its cisatracurium besilate injection from U.S Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's H1 net profit up 19.7 pct y/y

* Says H1 net profit up 19.7 percent y/y at 1.6 billion yuan ($242.26 million)

BRIEF-Jiangsu Hengrui Medicine and unit plans clinical trail for new drug SHR0302

* Says it and unit plans to start clinical trail for new drug SHR0302, which is a kind of selective depressant used for treatment of rheumatoid arthritis

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Docetaxel Injection from U.S Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's main product enters into National health insurance's list

* Says its main product ApatinibMesylate Tablets, a oral absorption, has been listed on National health insurance's list

BRIEF-Jiangsu Hengrui Medicine to pay A shares annual div for FY 2016 on May 31

* Says it will pay cash dividend of 0.135 yuan(before tax)/share and use additional paid-in capital to distribute 0.2 new shares/share for 2016 to shareholders of record on May 26

BRIEF-Jiangsu Hengrui Medicine's Q1 net profit up 18.6 pct y/y

* Says Q1 net profit up 18.6 pct y/y at 811.8 million yuan ($117.92 million)

BRIEF-Jiangsu Hengrui Medicine to set up unit with registered capital of 1.5 bln yuan

* Says it plans to set up medicine unit with registered capital at 1.5 billion yuan ($217.89 million)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up